Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Alliances symbols : AZN save search
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2-mutant Advanced Lung Cancer in DESTINY-Lung02 Phase II Trial
Published: 2023-09-11 (Crawled : 13:00) - biospace.com/
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: -3.31%
H: 1.02%
C: 0.97%
enhertu lung cancer tumor trial
LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targeting Antibody Drug Conjugate
Published: 2023-05-12 (Crawled : 21:00) - biospace.com/
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: 0.29%
H: 0.81%
C: -0.29%
lm-305 drug antibody license global agreement
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Showed Clinically Meaningful and Durable Responses Across Multiple HER2-expressing Tumor Types In DESTINY-PanTumor02 Phase II Trial
Published: 2023-03-06 (Crawled : 14:00) - biospace.com/
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: -1.01%
H: 0.59%
C: 0.03%
enhertu tumor trial
SOPHiA GENETICS Expands Partnership With AstraZeneca to Include Multimodal Approaches for Cancer Drug Development
Published: 2023-02-13 (Crawled : 14:20) - biospace.com/
SOPH | $5.05 0.8% 0.79% 32K
|
|
| O: 18.84%
H: 0.0%
C: -9.76%
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: -0.51%
H: 1.81%
C: 1.72%
partnership drug cancer
Resilience to Establish a Biomanufacturing Partnership with AstraZeneca and Purchase AstraZeneca’s Manufacturing Site in West Chester, Ohio
Published: 2022-11-29 (Crawled : 20:00) - biospace.com/
AZNCF | News | $138.73 -4.19% 3.7K
|
Health Technology
|
| O: -1.93%
H: 0.0%
C: 0.0%
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: 0.21%
H: 0.16%
C: -0.41%
partnership
Invitae Announces Partnership for Real-World Data Sharing to Inform Rare Cancer Research
Published: 2022-10-27 (Crawled : 12:00) - biospace.com/
NVTA | News | $0.019 0.0% 22M
|
Health Services
|
| O: 0.6%
H: 1.8%
C: -8.62%
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: -0.48%
H: 0.56%
C: -0.12%
partnership rare research cancer
Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics
Published: 2022-08-01 (Crawled : 23:00) - biospace.com/
AZNCF | News | $138.73 -4.19% 3.7K
|
Health Technology
|
| O: 2.39%
H: 0.0%
C: -0.9%
AVTX | $12.82 5.0% 4.76% 73K
|
Manufacturing
|
| O: 4.72%
H: 10.08%
C: -4.51%
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: 0.44%
H: 0.53%
C: -1.31%
il-18 therapeutics
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low metastatic breast cancer
Published: 2022-07-25 (Crawled : 12:00) - biospace.com/
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: 1.43%
H: 0.39%
C: -0.04%
enhertu granted review cancer her2- her2 metastatic breast cancer
GRAIL Announces Strategic Collaboration With AstraZeneca to Develop Companion Diagnostic Tests to Enable the Treatment of Early-Stage Cancer
Published: 2022-06-02 (Crawled : 17:00) - biospace.com/
ILMN | $124.41 3.46% 3.34% 1.3M
|
Health Technology
|
| O: -0.03%
H: 5.85%
C: 5.7%
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: 0.56%
H: 0.0%
C: 0.0%
treatment collaboration diagnostic cancer test
Proteros Expands Oncology Collaboration and License Agreement with AstraZeneca
Published: 2022-05-16 (Crawled : 11:00) - biospace.com/
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: 1.52%
H: 0.0%
C: 0.0%
collaboration license
AstraZeneca Joins Accumulus Synergy as a Sponsor to Accelerate the Delivery of Medicines to Patients
Published: 2022-05-12 (Crawled : 14:00) - biospace.com/
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: -2.18%
H: 1.85%
C: 1.55%
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
Published: 2022-05-05 (Crawled : 12:00) - biospace.com/
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: -1.35%
H: 0.4%
C: -1.2%
enhertu approved cancer breast cancer her2- her2 metastatic breast cancer
AstraZeneca progresses Ambition Zero Carbon programme with Honeywell partnership to develop next-generation respiratory inhalers
Published: 2022-02-22 (Crawled : 21:00) - biospace.com/
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: 3.24%
H: 0.18%
C: -1.6%
partnership program respiratory one
Samsung Biologics and AstraZeneca expand strategic manufacturing partnership to include COVID-19 and cancer therapy
Published: 2021-12-14 (Crawled : 07:00) - biospace.com/
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: 0.33%
H: 0.0%
C: 0.0%
covid-19 partnership covid therapy cancer
SAGA Diagnostics enters into an assay development agreement with AstraZeneca
Published: 2021-11-02 (Crawled : 18:00) - biospace.com/
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: 0.85%
H: 0.0%
C: 0.0%
diagnostics diagnostic
Second Clinical Trial Collaboration Initiated to Evaluate Datopotamab Deruxtecan in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Non-Small Cell Lung Cancer
Published: 2021-10-25 (Crawled : 13:00) - biospace.com/
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: 0.11%
H: 0.03%
C: -0.27%
lung cancer collaboration cancer trial initiated keytruda
Sierra Oncology Signs Exclusive Global In-Licensing Agreement with AstraZeneca for Novel BET Inhibitor to Expand Myelofibrosis Pipeline
Published: 2021-08-05 (Crawled : 21:00) - biospace.com/
SRRA | $54.99 0.04% 0.0%
|
Health Technology
|
| O: 0.0%
H: 5.03%
C: 3.82%
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: 1.48%
H: 0.46%
C: 0.43%
fibrosis license
Aridis Pharmaceuticals Announces Exclusive License of Suvratoxumab, a Phase 3-Ready Monoclonal Antibody, from AstraZeneca
Published: 2021-07-19 (Crawled : 13:15) - biospace.com/
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: -0.62%
H: 0.78%
C: 0.07%
ARDS | $0.0645 2.82% 41K
|
Health Technology
|
| O: -0.69%
H: 2.94%
C: -12.59%
antibody license phase 3
F-star Therapeutics Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors
Published: 2021-07-08 (Crawled : 14:15) - biospace.com/
FSTX | $7.12 0.0% 0
|
Health Technology
|
| O: 14.31%
H: 0.24%
C: -4.53%
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: -0.52%
H: 0.37%
C: -0.32%
license
Proteros Enters Into Oncology Collaboration and License Agreement With AstraZeneca
Published: 2021-06-02 (Crawled : 11:00) - biospace.com/
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: -0.66%
H: 0.62%
C: 0.39%
collaboration license
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.